Single User License
INR 100365
Site License
INR 200730
Corporate User License
INR 301095

Service Tax Additional

select a format

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500


Request a quote
Request a Customized research
Request for Sample Report

Recent Viewed Reports

Why Ken Reasearch?


While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"

EpiVax, Inc.-Product Pipeline Review-2015

EpiVax, Inc.-Product Pipeline Review-2015

  Request for Sample Report

Executive Summary

EpiVax, Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'EpiVax, Inc.-Product Pipeline Review-2015', provides an overview of the EpiVax, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of EpiVax, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of EpiVax, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of EpiVax, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the EpiVax, Inc.'s pipeline products

Reasons To Buy

Evaluate EpiVax, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of EpiVax, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the EpiVax, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of EpiVax, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of EpiVax, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of EpiVax, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

EpiVax, Inc. Snapshot 5

EpiVax, Inc. Overview 5

Key Information 5

Key Facts 5

EpiVax, Inc.-Research and Development Overview 6

Key Therapeutic Areas 6

EpiVax, Inc.-Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products-Monotherapy 10

EpiVax, Inc.-Pipeline Products Glance 11

EpiVax, Inc.-Early Stage Pipeline Products 11

Preclinical Products/Combination Treatment Modalities 11

Discovery Products/Combination Treatment Modalities 12

EpiVax, Inc.-Drug Profiles 13

Deimmunized FVIII 13

Product Description 13

Mechanism of Action 13

R&D Progress 13

Epi-13 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

helicobacter pylori infection vaccine 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

influenza vaccine [H1N1] 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

onabotulinumtoxin A 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

smallpox vaccine 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Synthetic Peptides for Allergy 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

Synthetic Peptides for Pompe disease 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

tuberculosis vaccine 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

TuliVax 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

equine encephalitis vaccine 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

HIV vaccine 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

influenza vaccine (H7N9) 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

EpiVax, Inc.-Pipeline Analysis 26

EpiVax, Inc.-Pipeline Products by Target 26

EpiVax, Inc.-Pipeline Products by Route of Administration 27

EpiVax, Inc.-Pipeline Products by Molecule Type 28

EpiVax, Inc.-Pipeline Products by Mechanism of Action 29

EpiVax, Inc.-Recent Pipeline Updates 30

EpiVax, Inc.-Dormant Projects 31

EpiVax, Inc.-Company Statement 32

EpiVax, Inc.-Locations And Subsidiaries 33

Head Office 33

Appendix 34

Methodology 34

Coverage 34

Secondary Research 34

Primary Research 34

Expert Panel Validation 34

Contact Us 34

Disclaimer 35

List of Tables

EpiVax, Inc., Key Information 5

EpiVax, Inc., Key Facts 5

EpiVax, Inc.-Pipeline by Indication, 2015 8

EpiVax, Inc.-Pipeline by Stage of Development, 2015 9

EpiVax, Inc.-Monotherapy Products in Pipeline, 2015 10

EpiVax, Inc.-Preclinical, 2015 11

EpiVax, Inc.-Discovery, 2015 12

EpiVax, Inc.-Pipeline by Target, 2015 26

EpiVax, Inc.-Pipeline by Route of Administration, 2015 27

EpiVax, Inc.-Pipeline by Molecule Type, 2015 28

EpiVax, Inc.-Pipeline Products by Mechanism of Action, 2015 29

EpiVax, Inc.-Recent Pipeline Updates, 2015 30

EpiVax, Inc.-Dormant Developmental Projects,2015 31

List of Figures

EpiVax, Inc.-Pipeline by Top 10 Indication, 2015 7

EpiVax, Inc.-Pipeline by Stage of Development, 2015 9

EpiVax, Inc.-Monotherapy Products in Pipeline, 2015 10

EpiVax, Inc.-Pipeline by Top 10 Target, 2015 26

EpiVax, Inc.-Pipeline by Top 10 Route of Administration, 2015 27

EpiVax, Inc.-Pipeline by Top 10 Molecule Type, 2015 28

EpiVax, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Current R&D Portfolio of EpiVax, Inc.; EpiVax, Inc. - Key Therapeutics; EpiVax, Inc. - Pipeline Overview and Promising Molecules; EpiVax, Inc. - News; EpiVax, Inc. - Latest Updates; EpiVax, Inc. - Pipeline; EpiVax, Inc. - Discontinued/Dormant Projects

Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204


Company Brochure

Engage with Us

query [@]